Overview Financials News + Filings Key Docs Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
WESTMOUNTAIN Co (WASM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/15/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/07/2019 |
8-K
| Quarterly results |
| 01/03/2019 |
8-K
| Quarterly results |
| 11/20/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/09/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/24/2018 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"CONSENT",
"2. Summary of Critical Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America . Principles of Consolidation The consolidated financial statements include the accounts of CytoBioscience, Inc., and its wholly owned subsidiaries, Cytocentrics Bioscience GmbH, Cytocentrics B.V. and SolubleBioscience, Inc. . All intercompany balances have been eliminated in consolidation. Foreign Currency Translation For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the year and the exchange rate at the balance sheet date, to translate the operating results and financial position to U.S. dollar, the...",
"WestMountain Company and CytoBioscience, Inc. Pro-Forma Condensed Consolidated Balance Sheet For the year ended December 31, 2017 WestMountain CytoBioscience Adjustments Pro Forma Combined" |
|
| 03/23/2018 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certi...|
Docs:
|
"Agreement of Merger and Plan of Reorganization by and among the Registrant, WASM Acquisition Corp. and CytoBioscience, Inc",
"Lock-up Agreement between the Registrant and the officers, directors and shareholders party thereto",
"Securities Purchase Agreement between the Registrant and the investor parties thereto",
"Investment Banking Agreement between Registrant and Divine Capital",
"Letter from EKS&H LLLP to the Securities and Exchange Commission",
"San Antonio, TX – – March 23, 2018 – CytoBioscience, Inc. , a revenue-generating ion channel screening business providing medical instrumentation and research services to organizations in the pharmaceutical and drug research market, today announced that it has closed a merger with WestMountain Company , effective March 19, 2018. On March 19, 2018, WestMountain entered into a Merger Agreement with CytoBioscience, Inc., a Delaware corporation . As per the terms of the Merger Agreement, a subsidiary of WestMountain merged into CytoBioscience, with CytoBioscience surviving the merger and becoming a wholly-owned subsidiary of WestMountain, and the shareholders of CytoBioscience becoming shareholders of WestMountain. Pursuant to terms of the Merger Agreement, all outstanding shares of capital st..." |
|
| 12/28/2017 |
8-K
| Other Events |
| 12/21/2017 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets |
| 11/30/2017 |
8-K
| Other Events |
| 10/19/2016 |
8-K
| Quarterly results |
| 09/28/2016 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 11/17/2011 |
8-K
| Form 8-K - Current report |
| 10/28/2011 |
8-K
| Form 8-K - Current report |
| 05/05/2011 |
8-K
| Form 8-K - Current report |
| 03/22/2010 |
8-K
| Form 8-K - Current report |
|
|